Indolylmaleimide derivatives
View Patent ↗Provided are compounds of formula (I) which are useful in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, obesity, syndrome X, impaired glucose tolerance, polycystic ovary syndrome, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock, e.g. traumatic brain injury. The compounds of formula I are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory disease or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimotos thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, e.g. angiopathy, diabetic proliferative retinopathy, diabetic macular edema, nephropathy, neuropathy and dawn phenomenon, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contract dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjoegren's syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn's disease or ulcerative colitis.
1. A method for treating acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I
wherein
R a is H; CH 3 ; CH 2 -CH 3 ; or isopropyl,
R b is H; halogen; C 1-6 alkoxy; or C 1-6 alkyl, and either
I. R is a radical of formula (a)
wherein
R 1 is piperazin-1-yl optionally substituted by CH 3 in position 3 or 4; or 4,7-diaza-spiro [2.5] oct-7-yl;
R 2 is Cl; Br; CF 3 ; or CH 3 ; and
R 3 is H; CH 3 ; or CF 3 ; R 2 being other than CH 3 or Cl when R 3 is H, R a is H or CH 3 , R b is H and R 1 is 4-methyl-1-piperazinyl; or
II. R is a radical of formula (b)
wherein
R 4 is piperazin-1-yl substituted in positions 3 and/or 4 by CH 3 ; or 4,7-diaza-spiro [2.5] oct-7-yl; R a being other than H or CH 3 when R 4 is 4-methyl-1-piperazinyl; or
II. R is a residue of formula (c)
wherein
R 14 is 4,7-diaza-spiro [2.5] oct-7-yl;
R 15 is halogen; CF 3 ; or CH 3 ; R 15 being other than CH 3 when R 16 is CH 3 , R a is H or CH 3 , and R b is H; and
R 16 is H; CH 3 ; CH 2 -CH 3 ; or CF 3 ; R 16 being other than H when R 15 is Cl, R a is H or CH 3 , and R b is H; or
IV. R is a radical of formula (d)
wherein
R 8 is 1-piperazinyl, 3-methyl-piperazin-1-yl or 4-benzyl-piperazin-1-yl; or
V. R is a radical of formula (e)
wherein
R 9 is 4,7-diaza-spiro [2.5] oct-7-yl; or 1-piperazinyl substituted in position 3 by methyl or ethyl and optionally in position 4 by methyl;
or a pharmaceutically acceptable salt thereof.
2. A method according to claim 1 wherein the compound of formula I is administered by topical route to the skin or to the eye.
3. A method according to claim 1 comprising co-administration, concomitantly or in sequence, of a therapeutically effective amount of a compound of formula I in free form or in pharmaceutically acceptable salt form, and a second drug substance, said second drug substance being an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug.
4. A pharmaceutical composition comprising a compound of formula I
or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable diluent or carrier therefore wherein
R a is H; CH 3 ; CH 2 -CH 3 ; or isopropyl,
R b is H; halogen; C 1-6 alkoxy; or C 1-6 alkyl, and either
I. R is a radical of formula (a)
wherein
R 1 is piperazin-1-yl optionally substituted by CH 3 in position 3 or 4; or 4,7-diaza-spiro [2.5] oct-7-yl;
R 2 is Cl; Br; CF 3 ; or CH 3 ; and
R 3 is H; CH 3 ; or CF 3 ; R 2 being other than CH 3 or Cl when R 3 is H, R a is H or CH 3 , R b is H and R 1 is 4-methyl-1-piperazinyl; or
II. R is a radical of formula (b)
wherein
R 4 is piperazin-1-yl substituted in positions 3 and/or 4 by CH 3 ; or 4,7-diaza-spiro [2.5] oct-7-yl; R a being other than H or CH 3 when R 4 is 4-methyl-1-piperazinyl; or
II. R is a residue of formula (c)
wherein
R 14 is 4,7-diaza-spiro [2.5] oct-7-yl;
R 15 is halogen; CF 3 ; or CH 3 ; R 15 being other than CH 3 when R 16 is CH 3 , R a is H or CH 3 , and R b is H; and
R 16 is H; CH 3; CH 2 -CH 3 ; or CF 3 ; R 16 being other than H when R 15 is Cl, R a is H or CH 3 , and R b is H; or
IV. R is a radical of formula (d)
wherein
R 8 is 1-piperazinyl, 3-methyl-piperazin-1-yl or 4-benzyl-piperazin-1-yl; or
V. R is a radical of formula (e)
wherein
R 9 is 4,7-diaza-spiro [2.5] oct-7-yl; or 1-piperazinyl substituted in position 3 by methyl or ethyl and optionally in position 4 by methyl;
or a pharmaceutically acceptable salt thereof.